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Intracellular generation of the photosensitiser, protoporphyrin IX, from a series of dipeptide derivatives of the haem precursor,
5-aminolaevulinic acid (ALA), was investigated in transformed PAM212 murine keratinocytes, together with studies of their
intracellular metabolism. Porphyrin production was substantially increased compared with equimolar ALA using N-acetyl terminated
phenylalanyl, leucinyl and methionyl ALA methyl ester derivatives in the following order: Ac-L-phenylalanyl-ALA-Me, Ac-L-methionyl-
ALA-Me and Ac-L-leucinyl-ALA-Me. The enhanced porphyrin production was in good correlation with improved photocytotoxicity,
with no intrinsic dark toxicity apparent. However, phenylalanyl derivatives without the acetyl/acyl group at the N terminus induced
significantly less porphyrin, and the replacement of the acetyl group by a benzyloxycarbonyl group resulted in no porphyrin
production. Porphyrin production was reduced in the presence of class-specific protease inhibitors, namely serine protease inhibitors.
Using siRNA knockdown of acylpeptide hydrolase (ACPH) protein expression, we showed the involvement of ACPH, a member of
the prolyl oligopeptidase family of serine peptidases, in the hydrolytic cleavage of ALA from the peptide derivatives. In conclusion,
ALA peptide derivatives are capable of delivering ALA efficiently to cells and enhancing porphyrin synthesis and photocytotoxicity;
however, the N-terminus state, whether free or substituted, plays an important role in determining the biological efficacy of ALA
peptide derivatives.
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Photodynamic therapy (PDT) is a promising modality for cancer
treatment that utilises tumour-specific accumulation of a photo-
sensitiser, followed by irradiation with light at an appropriate
wavelength (Bonnett, 1995). The use of 5-aminolaevulinic acid
(ALA) for PDT has received considerable interest owing to the
metabolism of ALA through the haem biosynthetic pathway (Peng
et al, 1997) to the photosensitiser protoporphyrin IX (PpIX).
Following the exogenous administration of ALA, PpIX is generated
intracellularly, which can then be activated by visible light for PDT
treatment. ALA-PDT does exhibit a degree of intrinsic tumour
selectivity owing to differing tumour levels of enzymes in the haem
pathway (e.g. ferrochelatase) leading to higher tumour PpIX levels.
The principal advantages of ALA-PDT are the short duration of
skin photosensitivity and its efficacy using both topical and oral
administration (Peng et al, 1997; Brown et al, 2004).
A significant drawback of ALA-PDT is the fact that ALA is a
zwitterion at physiological pH resulting in low lipid solubility and
limiting passage through biological barriers such as cellular
membranes. To overcome this problem, several chemical
approaches have been attempted to improve the incorporation of
ALA and also its selectivity. One approach has been to use more
lipophilic ALA derivatives, such as alkyl or ethyleneglycol esters,
which are potential substrates for cellular esterases (Kloek and
Beijersbergen, 1996; Gaullier et al, 1997; Berger et al, 2000;
Uehlinger et al, 2000), or different delivery systems including
dendrimers (Battah et al, 2001, 2006; Di Venosa et al, 2006),
or liposomes (Casas et al, 2002; Casas and Batlle, 2006).
5-Aminolaevulinic acid prodrug ester derivatives have been widely
studied (Kloek and Beijersbergen, 1996; Peng et al, 1996; Gaullier
et al, 1997; Kloek et al, 1998; Casas et al, 1999; Eleouet et al, 2000;
Brunner et al, 2003; Lopez et al, 2004), in particular the methyl and
hexyl ester derivatives, and approval has been granted for the
treatment of actinic keratosis and basal cell carcinoma using the
methyl ester derivative in Europe and Australia. The use of alkyl
esters of ALA results in a nonspecific distribution of ALA in all cell
types, but with an increased PpIX production (Webber et al, 1997;
Uehlinger et al, 2000) in tumour cells. In this regard, Casas et al
(1999) and Berger et al (2000, 2003) have conjectured that the
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provide a suitable means of both facilitating transdermal delivery
and also improved targeting to cancerous cells.
In an attempt to improve uptake and cell selectivity of ALA and
its derivatives, we investigated PpIX formation and metabolism
mechanisms using peptide ALA prodrugs that represent potential
substrates for cell-surface and cytoplasmic peptidases and
esterases. A recent investigation of ALA prodrugs showed that
the L-enantiomer of Ac-Phe-ALA-Me, 1, was capable of delivering
ALA to cells, with an enhancement of PpIX and PDT effectiveness,
comparable with the results obtained with the hexyl ester
derivative, ALA-Hex (Bourre ´ et al, 2008). The ALA residue was
masked on one side through a peptide bond and on the other side
through an ester linkage, which were then cleaved enzymatically
within the cells to liberate the ALA. We also showed that the
D-enantiomer did not induce any PpIX production, which would
be consistent with the stereospecific enzymatic cleavage acting
only on the L-forms of such prodrugs.
In this study, we have focused on several ALA peptide
derivatives using different amino acids and have studied the
influence of structurural modification at the N terminus by
changing the N-terminal blocking group. We then studied the
metabolism mechanism involved in the release of ALA using class
protease inhibitors and silencing of mammalian acylpeptide
hydrolase activity (ACPH, EC 3.4.19.1) using small interfering
RNA (siRNA) technology. Acylpeptide hydrolase, a member of the
prolyl oligopeptidase family of serine peptidases, is an exo-
peptidase that removes acylated amino-acid residues from the
N terminus of oligopeptides.
MATERIALS AND METHODS
Chemicals
5-Aminolaevulinic acid was purchased from Sigma-Aldrich Ltd
(Gillingham, UK).
The structures of ALA peptide derivatives are shown in Figure 1.
The synthesis of compounds 1–5 (Rogers et al, 2005) and 8
(Bourre ´ et al, 2008) has already been reported. Compounds 6, 9
and 10 were synthesised according to the same procedure with
minor modifications. Stock solutions of compounds 1 and 2 were
prepared by dissolving at 10mM in 0.01 M HCl and stored at
 201C. Compound 3 was dissolved at 100mM in 0.1 M HCl solution
and stored at  201C.
Cell culture
The spontaneously transformed murine keratinocyte cell line,
PAM212 (obtained from Professor R Groves, King’s College,
London), was cultured in RPMI-1640 medium (Gibco BRL, Life
Technologies Ltd, Paisley, UK) containing L-glutamine (2mM) and
phenol red, supplemented with 10% foetal calf serum (FCS; Sigma-
Aldrich Ltd) and penicillin and streptomycin (500Uml
 1 and
0.5mgml
 1; Gibco BRL). The cells were routinely grown as
monolayers in 75-cm
2 culture flasks (TPP; Helena Bioscience,
Gateshead, UK) at 371C, 5% CO2 atmosphere until confluent.
Porphyrin synthesis determination
Cells were seeded into g-sterilised 96-well plates (Orange Scientific,
Triple Red Laboratory Technologies, Long Crendon, UK) at a
density of 5 10
4 cells per well for 48h. After removing the culture
medium, the wells were washed with PBS and incubated with
freshly prepared solutions of ALA or ALA peptide derivatives
1–10: 0.1ml of serum-free medium containing varying prodrug
concentrations was added to a designated series of wells. Each
plate contained control wells with cells but without added drug for
the determination of the background reading and reference wells
containing cells incubated with the same ALA concentrations. For
drug incubation, serum-free medium was used as serum is known
to cause the release of PpIX from cells, thus resulting in the loss of
fluorescence signal (Kloek et al, 1998).
Code R1 R2 R3 Name 
1 H3COC- -CH2-C6H5 -CH3 Ac-Phe-ALA-Me 
2 H3COC- -H  -CH3 Ac-Gly-ALA-Me 
3 H3COC- -CH3 -CH3 Ac-Ala-ALA-Me 
4 H3COC- -CH(CH3)2 -CH3 Ac-Val-ALA-Me 
5 H3COC- -CH2-CH(CH3)2 -CH3 Ac-Leu-ALA-Me 
6 H3COC- -CH 2CH2SCH3 -CH3 Ac-Met-ALA-Me 
7 H3COC- -CH2-C6H5 -H Ac-Phe-ALA 
8 H- -CH2-C6H5 -CH3 Phe-ALA-Me 
9 H- -CH2-C6H5 -H Phe-ALA 
10 C6H5-CH2-OCO -CH2-C6H5 -CH3 Z-Phe-ALA-Me 
R1HN
H
N
R2
O
O
OR3
O
Figure 1 General structure of ALA peptide derivatives.
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sThe fluorescence signal from each well was measured with a
spectrometer Perkin-Elmer LS 50B fluorescence spectrometer
(Perkin Elmer, Beaconsfield, UK) using 410-nm excitation and
635-nm emission wavelengths, with slit widths set to 10nm and the
internal 530 nm longpass filter used on the emission side; spectral
scans were recorded between 600 and 750nm to check for the
presence of any porphyrins other than PpIX (Battah et al, 2006).
The mean fluorescence intensity (expressed in arbitrary units) was
calculated after subtraction of the control values. Intensity
calibrations were performed using rhodamine B embedded in a
Perspex disc as a standard.
Photodynamic treatment
Cells were seeded into 96-well plates at a density of approximately
2 10
4 cells per well. Following incubation for 48h, the cells were
washed with PBS, and 0.1ml of solutions containing ALA, 1, 6, 7, 8
and 9 at 0.01mM were added to their designated wells for 4-h
incubation periods. The plates were irradiated with a fluence of
2Jcm
 2 using a LumiSource lamp (PCI Biotech, Oslo, Norway)
that emits a uniform field of low-power blue light over an area of
14 32cm. Peak output is around 420nm, which overlaps well
with the PpIX Soret band. Immediately following irradiation, the
medium was replaced and cells were incubated for a further 24h.
Cell cytotoxicity was determined using the 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay: cells were
incubated with medium containing MTT (1mgml
 1 dissolved in
full RPMI-1640 medium) for 3h. The insoluble end product
(formazan derivatives) was dissolved in 0.1ml of dimethylsulph-
oxide after removing the medium. Ultraviolet absorption was
quantified at 570nm using a 96-well plate reader (MR 700
Dynatech; Dynex, Worthing, UK). The mean cell survival was
calculated for each prodrug at every concentration tested and
expressed as a percentage of control (incubated with the
compounds but not irradiated) cell survival values. For the
determination of ‘dark’ toxicity of the compounds, well plates
were prepared in the same manner as above but without
irradiation.
Peptidase activities
Influence of protease inhibitors Evaluation of PpIX production
by fluorescence recording in living cells, performed as described
earlier above, was determined after incubation with a range
of protease inhibitors. The protease inhibitors were added to
cell cultures 10min before adding ALA or compound 1 at 0.1mM
and fluorescence increases were recorded. Protease inhibitors
used are protease inhibitor cocktail (1:250), aprotinin (competi-
tive serine protease inhibitor) (20mM), AEBSF (irreversible
serine protease inhibitor) (200mM), 2,20-bipyridyl (metallo-
protease inhibitor) (20mM), bestatin (metalloaminopeptidase
inhibitor) (100mM), E64 (cysteine protease inhibitor) (10mM),
leupeptin (trypsin-like protease and cysteine protease inhibi-
tor) (100mM) and captopril (angiotensin-converting enzyme
inhibitor) (20mM). Protease inhibitors were purchased from
Sigma-Aldrich Ltd.
Acylpeptide hydrolase assay PAM212 cells were solubilised with
CelLytic and centrifuged at 13000g for 5min. The supernatant
(cell lysate) was assayed for ACPH activity using 4mM acetyl-
alanine p-nitroanilide (AcApNA) (Kobayashi and Smith, 1987;
Scaloni et al, 1992b; Yamaguchi et al, 1999) as substrate in 20mM
Tris-HCl (pH 7.4) (Scaloni et al, 1994). The influence of thiol
reagent pHMB and histidine-modifying reagent DEP on ACPH
activity was also assessed. The solution was kept at 371C and the
liberated p-nitroaniline from AcApNA was measured at 405nm
using a 96-well plate reader (MR 700 Dynatech) at 0, 10, 30, 60 and
120min.
The influence of ALA, Ac-Ala-Ala-Ala-Ala-OH and 1 on ACPH
activity was evaluated as described above except that the cell lysate
was preincubated with these compounds for 1h.
Knockdown of ACPH protein expression with siRNA
For each well transfected in 12-well plates, 60pmol siRNA (ACPH
siRNA; Invitrogen, Paisley, UK) was diluted in 200ml of serum-free
Opti-MEM I Medium (Invitrogen). Then 2ml of Lipofectamine
RNAiMAX was added to each well containing the diluted siRNA
molecule and incubated for 20min at room temperature.
PAM212 cells (3 10
4 per ml in RPMI with serum, without
antibiotics) were seeded in 12-well plates (1ml per well) and
allowed to grow for 72h, 371C, 5% CO2, before experimentation.
The PpIX synthesis was assessed after incubation with 0.5mM of
ALA or 1 during 4h, and then washed with PBS. One ml of CelLytic
(Sigma-Aldrich Ltd) was added and incubated during 15min at
room temperature, and then the cells were mechanically scraped.
Cell extracts were centrifuged at 1800g for 10min to remove the
cell debris, and the supernatant containing the PpIX was collected.
The fluorescence of extracted PpIX was measured as described
earlier.
Statistical analysis
The results are displayed graphically, with error bars representing
standard deviations. Differences are considered to be significant
using the unpaired t-test.
RESULTS
PpIX synthesis determination
The PpIX produced by exposure to compounds 1–6, compared
with ALA, is shown in Figure 2A and B. At 0.01mM (Figure 2A),
ALA was not able to produce any measurable PpIX; however, a
high amount of PpIX was produced with 1. Compounds 3, 5 and 6
also induced some PpIX production but to a lesser extent.
However, compounds 2 and 4 were not able to induce measurable
PpIX levels at this concentration. Using 0.1mM (Figure 2B), the
level of PpIX was enhanced by a factor 3.5 with 1, 5 and 6
compared with ALA. Compounds 3 and 4 enhanced the PpIX
production by a factor 1.5; however, 2 produced less PpIX
compared with ALA.
Fluorescence pharmacokinetics
The kinetics of intracellular porphyrin fluorescence induced by
exposure to compounds 1, 7–9 and ALA in the PAM212 cell line
are shown in Figure 3A and B. Fluorescence spectral profiles were
consistent with the production of PpIX, and peak emission at
635nm was used for the pharmacokinetic measurements. Increas-
ing porphyrin levels were observed with increasing incubation
times from 2 to 6h. For the lowest concentration tested, 0.01mM,
no PpIX production was observed with ALA, 8 and 9. However, 1
and 7 induced high levels of PpIX, 1 inducing the higher level
regardless of the incubation time. When the concentration was
increased to 0.1mM, all the compounds induced PpIX production,
with a significant increase found with 1 and 7. However, peptides 8
and 9, compounds without an acetyl group at the N terminus,
induced less PpIX compared with ALA; these results were also
observed in human epidermoid carcinoma A431 cells and colon
carcinoma Caco-2 cells (data not shown). No significant difference
was observed for 1 when the concentration was increased.
Figure 4A shows the results of experiments carried out with
compound 10 vs 1 and ALA, to observe the effect of the Z group at
the N terminus instead of the acetyl group in compound 1.N o
PpIX production was observed with 10 compared with ALA,
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Figure 4B, the effect of the presence of the amino acid in the
prodrug derivative was studied, and for this purpose, the molecule,
Ac-ALA-Me, was synthesised. No PpIX production was observed
with Ac-ALA-Me compared with ALA or 1, whatever the
incubation time or the concentration used.
Photodynamic treatment
The phototoxicity was investigated after 4h of incubation with
0.01mM of ALA, 1, 6, 7, 8 and 9. The percentage of cell survival
with respect to control cells (without compounds) was calculated
and plotted as shown in Figure 5. No dark toxicity was found for
any of the compounds. Compounds 1, 6 and 7 exhibited a high
phototoxicity with less than 5% cell survival. However, no
phototoxicity was observed with ALA, 8 and 9, with 100, 82 and
84% of cell survival, respectively.
Peptidase activities: acylpeptide hydrolase assay
Influence of protease inhibitors To obtain information concern-
ing the enzymatic activities involved in releasing free ALA from
these precursors, we evaluated PpIX production after incubation
with ALA or compound 1 in the presence of class-specific protease
inhibitors (Figure 6): protease inhibitor cocktail, aprotinin, AEBSF,
2,20-bipyridyl, bestatin, E64, leupeptin and captopril.
Aprotinin, bestatin, 2,20-bipyridyl, E64, leupeptin and captopril
had no significant effect. However, the PpIX production was
reduced by serine protease inhibitor AEBSF.
Acylpeptide hydrolase assay To confirm ACPH activity in
PAM212 cells, we tested the ACPH activity of cell lysates using
AcApNA as a substrate (Scaloni et al, 1992b, 1994; Sharma and
Ortwerth, 1993; Yamaguchi et al, 1999) and the influence of
inhibitors. Acylpeptide hydrolase has earlier been reported to be
inactivated with the thiol reagent pHMB (Scaloni et al, 1994) and
histidine-modifying reagent DEP (Scaloni et al, 1992b). As shown
in Figure 7A and B, the PAM212 cell lysate showed some ACPH
activity in the absence of inhibitors. However, the ACPH activity
was rapidly and completely inhibited by pHMB (Figure 7A) and
moderately by DEP (Figure 7B).
To assess if our peptide prodrugs are potential substrates for
ACPH, we studied the influence of the concentration of the drug on
AcApNA hydrolysis (Figure 7C). We evaluated the influence of
ALA, phenylalanyl derivative 1 (the most efficient of the peptide
derivatives) and Ac-Ala-Ala-Ala-Ala-OH, which is a substrate for
ACPH (Krishna and Wold, 1992; Sokolik et al, 1994).
5-Aminolaevulinic acid exerted no significant influence on ACPH
activity, whatever the concentration used. The ACPH substrate,
Ac-Ala-Ala-Ala-Ala-OH, reduced the ACPH activity by 42 and
47%, respectively, with 5 and 10mM. Compound 1 exhibited
similar effects by a reduction of activity by 25 and 41% with 5 and
10mM. However, for lower concentrations tested, the activity was
reduced by 22 and 28%, respectively, with 0.5 and 1mM with 1;n o
reduction of the activity was observed with Ac-Ala-Ala-Ala-Ala-
OH at these concentrations, showing that 1 has a higher affinity for
ACPH compared with Ac-Ala-Ala-Ala-Ala-OH.
Knockdown of ACPH protein expression with siRNA
To further define the role of ACPH in the ALA peptide derivative
hydrolysis, RNA interference for ACPH was employed by
transfection of cells with the specific siRNA against murine ACPH
mRNA (Figure 8). Inhibition of the ACPH protein expression by
siRNA reduced the PpIX production significantly by 53% after
incubation with compound 1. However, when cells were incubated
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Figure 2 PpIX fluorescence in PAM212 cells after incubation at 371C for
4h with 0.01mM (A) or 0.1mM (B) of ALA peptide derivatives 1–6 and
ALA. Error bars show standard deviations. *Po0.01 (ALA vs other
compounds).
A
–1
1
3
5
7
9
11
13
15
17
ALA 1 7 8 9
ALA 1 7 8 9
F
l
u
o
r
e
s
c
e
n
c
e
 
(
a
.
u
.
)
B
–1
1
3
5
7
9
11
13
15
17
F
l
u
o
r
e
s
c
e
n
c
e
 
(
a
.
u
.
)
Figure 3 PpIX fluorescence in PAM212 cells exposed at 371C for 2
(’), 4 ( ) and 6h ( ) with 0.01mM (A) or 0.1mM (B) of ALA, 1, 7–9.
Error bars show standard deviations. *Po0.01 (ALA vs other compounds).
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swith ALA, the PpIX production was only reduced by 25%. These
results convincingly indicate that the expression of ACPH protein
is involved in the hydrolysis of ALA peptide derivatives.
DISCUSSION
The targeted delivery of anticancer drugs to specific cell types,
including photosensitisers in PDT, is of crucial importance for
minimising treatment side effects. For the ALA prodrugs to exert a
pharmacological effect, the derivatives must be able to reach the
target sites at a sufficient concentration; this depends on the
presence on the target cells of the necessary transport systems able
to deliver them into the cytoplasm (Doring et al, 1998; Langer et al,
1999; Novotny et al, 2000; Rud et al, 2000; Irie et al, 2001) and their
ability to undergo an efficient enzymatic hydrolysis to liberate ALA
for the subsequent conversion to protoporphyrin IX (Peng et al,
1996).
A major challenge in ALA-PDT at the present time is the need to
achieve a more effective penetration of ALA into target tissues or
the cells of pathogenic organisms. A limitation to the use of ALA in
PDT results from its low lipid solubility, a consequence of its
zwitterionic character at physiological pH that leads to poor
penetration through biological barriers such as cellular mem-
branes. This problem has partly been addressed through the
synthesis of lipophilic ester prodrugs that provide improved
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Figure 4 (A) PpIX fluorescence in PAM212 cells exposed at 371C for 2
(’), 4 ( ) and 6h ( ) with 0.1, 0.3 and 0.5mM of ALA or 10. Error bars
show standard deviations. *Po0.01 (ALA vs 10). (B) PpIX fluorescence in
PAM212 cells exposed at 371C for 2 (’), 4 ( ) and 6h ( ) with 0.1mM
of ALA, 1, Ac-ALA-Me. Error bars show standard deviations. *Po0.01
(ALA vs other compounds).
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Figure 5 Toxicity (&) and phototoxicity (’) after incubation with
ALA, 1, 6, 7, 8 and 9 at 0.01mM in PAM212 cell lines assessed by the MTT
assay: cells were incubated with the compounds for 4h and irradiated with
blue light (2Jcm
 2). Error bars show standard deviations.
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scellular uptake and are metabolised into PpIX following the action
of nonspecific intracellular esterases (Lopez et al, 2004). A more
recent development concerns the preparation of peptide-based
ALA prodrugs, and we (Casas et al, 1999; Rogers et al, 2005) and
others (Berger et al, 2000, 2003) have described the synthesis and
evaluation of short ALA peptide derivatives in which either the
amino or the carboxyl functions of the latter are masked, thereby
providing improved physical properties and the potential for cell
line-specific ALA release, according to which peptidases are
expressed. We have shown earlier the feasibility of using
L-phenylalanyl-ALA derivatives (Bourre ´ et al, 2008) to enhance
intracellular porphyrin production and improve the efficacy of
photodynamic treatment.
In this study, we investigated the properties of a larger number
of ALA peptide derivatives containing different amino acids and
studied the influence of structural modification in the form of the
presence or absence of an N-terminal blocking group, compared
with ALA itself (Figure 1). The presence of the N-acetyl group at
the N termini of compounds 1–7 prevents decomposition of the
derivative at physiological pH. Consequently, these peptide
derivatives do not need to be prepared and then dissolved as
hydrochloride salts, unlike ALA. We have also prepared the
corresponding non-acetylated derivatives, 8 (L-Phe-ALA-Me) and
the free acid 9 (L-Phe-ALA). However, these compounds show
limited stability, presumably due to the cyclisation of the
N-terminal amino group of phenylalanine onto the carbonyl
moiety of the ALA residue, generating a six-membered Schiff base
intermediate that may react further (Berger et al, 2003), which
therefore necessitates preparation just before the experiment.
The determination of protoporphyrin IX production (Figure 2)
showed that compounds 1–6 were found to be capable of being
taken up by cells and releasing ALA for subsequent conversion to
PpIX, with a significant enhancement of PpIX production
compared with ALA for compounds 1, 6, 5, 4 and 3, respectively.
The effect of modification of the prodrug structure at the C or N
terminus on PpIX production, compared with ALA, was then
studied. Fluorescence spectroscopy was employed to detect and
quantify the PpIX accumulation induced by the compounds 1 and
7–10 vs ALA in the transformed keratinocyte PAM212 cell line.
Compound 7 (Figure 3), corresponding to the free acid of
compound 1, showed a significant increase compared with ALA,
with a PpIX level comparable with compound 1. However, 8 and 9,
compounds without an acetyl group at the N terminus, induced
less PpIX compared with ALA. The acetyl group at the N terminus,
therefore, seems to play an important role, in metabolic processes
leading to the production of PpIX, whereas masking the C
terminus as a methyl ester does not exert a major effect. In
agreement with the fluorescence pharmacokinetic data, photo-
dynamic treatment of cells incubated with ALA, 1, 6, 7, 8 and 9
(Figure 5) showed that the photocytotoxicity correlated with the
PpIX fluorescence level described in Figure 3A. Following the
illumination of cells incubated with compounds 1, 6 and 7, cell
survival was significantly reduced (Figure 5) compared with
equimolar ALA. However, ALA, 8 and 9 exhibited no phototoxicity
in agreement with the lack of porphyrin produced by these
compounds.
Substitution (compound 10) on the N terminus by a benzyl-
oxycarbonyl (Z) group, instead of the acetyl group, abolished the
activity of the compound with no PpIX production observed, as
shown in Figure 4A. In pig skin explants, we have shown earlier
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Figure 7 Inactivation of acylpeptide hydrolase by thiol reagent pHMB
(A) and histidine-modifying reagent DEP (B). Cellular extracts were
incubated with 0mM (E), 0.01mM (’), 0.05mM (m), 0.2mM (*) and
0.5mM (K) of pHMB or DEP. (C) Influence of ALA (*), Ac-Ala-Ala-Ala-
Ala-OH (m) and 1 (’) on acylpeptide hydrolase activity. Cellular extracts
were preincubated with a range of concentration of prodrugs during 1h,
then the enzyme activity was determined with AANA as substrate as
described earlier after 30min.
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Figure 8 Relative PpIX production (%) in PAM212 cells treated with
siRNA directed towards ACPH mRNA. Seventy-two hours after
transfection, cells were incubated with 0.5mM of ALA or 1 during 4h at
371C. Error bars show standard deviations. *Po0.01 (vs no transfected
cells).
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s(Bourre ´ et al, 2008) that 1 was able to induce higher porphyrin
fluorescence by a factor 3 compared with ALA at 0.2mM drug
concentration; however, once again no porphyrin production was
found with the Z derivative (data not shown). Finally, the presence
of the amino acid in the derivative was studied, and for this
purpose the molecule, Ac-ALA-Me, was synthesised (Figure 4B).
No PpIX production was observed with Ac-ALA-Me compared
with ALA or 1, whatever the incubation time or the concentration
used. In conclusion, the nature of the N terminus appears to play
an important role in the efficacy of these compounds, which
indicates that the release of the substituted amino acid intra-
cellularly is probably conditioned by a specific enzymatic activity.
Berger et al (2000) have described the evaluation of several
L-amino-acid ALA derivatives and their PpIX production in
different cell lines (rat endothelial EC212, human endothelial
HCEC and lung carcinoma A549 cells). Included in this study was
compound 8, which showed high yields of PpIX in all cell lines
compared with other neutral and charged amino-acid derivatives
investigated. We have also observed PpIX production with this
derivative in the PAM212 cell line, although it is far less efficient
than the corresponding N-terminally acetylated derivative 1, which
is moreover far more stable at physiological pH. Berger et al (2000)
showed the involvement of aminopeptidase N/M activity in ALA
release from 8 and other prodrugs in various cell lines. These
enzymes, which are located both at the cell surface and in the
cytoplasm, show a strong preference for substrates that contain
neutral amino-acid residues at the N terminus. In agreement with
our findings here, Berger et al (2000) observed no PpIX production
in cells from peptide derivatives in which the N terminus was
blocked with an alkoxycarbonyl group (t-butoxycarbonyl, Boc).
Such derivatives are not expected to be substrates for aminopepti-
dase N/M. Uncapped compounds 8 and 9, which are potential
substrates for aminopeptidase N/M, showed low PpIX production.
We did, however, find that PAM212 cells had APN/M activity using
the specific substrates H-Ala-bNA, H-Phe-bNA and H-Leu-bNA
(data not shown), suggesting that the lack of PpIX production with
8 and 9 may be due to poor cellular uptake.
We also studied the influence of the aminopeptidase inhibitors
(amastatin, bestatin and aminopeptidase N inhibitor) on PpIX
production with 1 (data not shown), but none of them were able to
reduce the PpIX production, confirming that the N-acetyl ALA
peptide derivatives studied here should not be substrates for
aminopeptidases and that these enzymes are not involved in the
mechanism of ALA release from these ALA peptide derivatives. It
is more probable that endopeptidases or exopeptidases, which can
act on N-terminally acylated derivatives, are involved. On the basis
of the results described here, it is probable that the N-acetylated
amino-acid residue is cleaved to release ALA or ALA-Me for
conversion to PpIX. We hypothesised that the acylpeptidyl residue
is most likely released by the acylpeptide hydrolase (ACPH, EC
3.4.19.1), a member of the prolyl oligopeptidase family of serine
peptidases, and an exopeptidase that removes acylated amino-acid
residues from the N terminus of oligopeptides.
To obtain further information concerning the enzymatic
activities involved in releasing free ALA from these precursors,
we evaluated PpIX production in the presence of class-specific
protease inhibitors (Figure 6): protease inhibitor cocktail,
aprotinin, AEBSF, 2,20-bipyridyl, bestatin, E64, leupeptin and
captopril. The PpIX production was reduced by the serine protease
inhibitors, aprotinin and AEBSF.
The ACPH activity of the PAM212 cellular extract was then
assessed using pAcNA as a substrate (Scaloni et al, 1992b, 1994;
Sharma and Ortwerth, 1993; Yamaguchi et al, 1999). The PAM212
cell lysate showed some ACPH activity in the absence of inhibitors.
However, the ACPH activity was rapidly and completely inhibited
by pHMB (Figure 7A) and moderately by DEP (Figure 7B). The
influence of preincubation of cell extracts with ALA peptide
derivative on the ACPH activity was studied, showing that
compound 1 induced a reduction of the activity by 41% at
10mM. These results were similar to those obtained with Ac-Ala-
Ala-Ala-Ala-OH, an ACPH substrate, and are therefore consistent
with the involvement of the serine protease AC0PH in ALA release
from ALA-containing peptide derivatives.
The final functional argument to prove the causal relationship
between ACPH expression/activity and ALA peptide derivative
hydrolysis inducing the PpIX formation is now provided by the
fact that the PpIX formation can be reduced by siRNA interference
directed towards ACPH (Figure 8). Sequence-specific post-
transcriptional gene silencing by double-stranded RNA (dsRNA),
also called RNA interference, is conserved in a diverse variety of
organisms (Gupta et al, 2004). RNA interference is mediated by
siRNAs that are produced from long dsRNAs of exogenous or
endogenous origin by an endonuclease of the ribonuclease-III
type. The resulting siRNAs are 21–23 nucleotides long and are
incorporated into a nuclease complex. After binding to the RNA-
induced silencing complex, complementary mRNA is cleaved
(Elbashir et al, 2001). Here, we described siRNA sequences
effective in reducing ACPH expression on reverse transfection,
leading to a significant PpIX reduction by 53% with compound 1.
These results confirm that the expression of ACPH protein is
involved in the hydrolysis of the ALA peptide derivatives.
Moreover, it is known that the enzyme is preferentially directed
towards peptides with Ac-Ala- and Ac-Met-, and tolerates a variety
of residues in the second position (P10) (Jones and Manning, 1988;
Radhakrishna and Wold, 1989; Krishna and Wold, 1992; Sokolik
et al, 1994; Raphel et al, 1999). This is consistent with the results
obtained with compound 6 corresponding to methionyl derivative,
which shows a higher PpIX enhancement compared with the other
derivatives, apart from 1, which also induces similar levels of PpIX.
Compound 3, corresponding to the alanyl derivative, induced a
PpIX enhancement compared with ALA but not as high as that of
the methionyl or phenylalanyl derivative. However, this result does
not reflect the ACPH substrate specificity described in the
literature (Kobayashi and Smith, 1987; Krishna and Wold, 1992;
Sokolik et al, 1994), in which it was found that Ac-Ala-Ala-Ala is
the substrate that exhibits the highest hydrolysis efficiency. The
hydrolysis parameters were generally determined on specific
sequences by studying the influence of the position of one amino
acid in the sequence on the hydrolysis rate. In the case of the
compounds studied here, no corresponding data are available on
the ACPH activity towards peptides including 5-ALA, which mimic
Gly-Gly dipeptides, that is with a general sequence Ac-aa-Gly-Gly.
These discrepancies need to be examined in terms of the sequence
in which the presumed specificity-determining amino acids were
displayed in the different substrates, and it would be an
oversimplification to merely state that ACPH requires a given
residue in position P1, P10,P 2 0 and so on. One also has to consider
how the activity will be interdependent on the presence of these
residues in conjunction with all the other constituents of the
peptide substrate. A further potentially important factor is that
owing to the presence of the phenyl group, the phenylalanyl
derivative is more lipophilic than the alanyl derivative, which
should enhance the relative cellular uptake of the phenylalanyl
derivative and therefore the measured porphyrin level.
In conclusion, the results in this study provide further evidence
that the conjugation of ALA with specific amino acids is a promising
approach for inducing enhanced intracellular porphyrin production
for photodynamic therapy. As peptidase expression is generally
different between normal and tumour cells or tissues, there is the
possibility of more specific targeting, particularly by modulating the
N-terminal portion. Our derivatives showed a specific affinity for
ACPH, an enzyme the expression of which is higher in tumour cells
compared with normal cells (Schoenberger et al, 1986). Indeed,
although ACPH activity is practically absent in A549 small-cell lung
carcinoma cells (Scaloni et al, 1992a), we were still able to observe low
levels of PpIX production after incubation with compound 1 (data
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snot shown). The peptide prodrugs described herein may be suitable
for both topical use (e.g. for bladder and cervical cancers in addition
to basal cell carcinomas) and for systemic administration in view of
their low inherent toxicity (Bourre ´ et al, 2008) compared with
the hexyl ester of ALA. Further studies to optimise peptide-based
ALA delivery are currently in progress using more complex
ALA-containing amino-acid sequences and cell-penetrating peptide
carriers (Dixon et al, 2007).
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